Sugi Predict

Sugi Predict / Compounds / SCHEMBL193140

SCHEMBL193140

SCHEMBL193140

COC(=O)N[C@H](C(=O)O)[C@@H](C)OC

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ SLC1A3 P43003 2/20 0.33
▸ SLC1A2 P43004 1/20 0.31
▸ SLC1A1 P43005 1/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ TP53 P04637 1/20 0.31
▸ TYR P14679 1/20 0.31
▸ TGFBR1 P36897 1/20 0.31
▸ CTSS P25774 1/20 0.30
▸ CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6121051 1.00 PYGL (0.35) PYGLCYP2C9ALDH1A1SLC1A3SLC1A2
SCHEMBL901561 1.00 PYGL (0.35) PYGLCYP2C9ALDH1A1SLC1A3SLC1A2
SCHEMBL903751 1.00 PYGL (0.35) PYGLCYP2C9ALDH1A1SLC1A3SLC1A2
SCHEMBL241112 1.00 PYGL (0.35) PYGLCYP2C9ALDH1A1SLC1A3SLC1A2
SCHEMBL901563 1.00 PYGL (0.35) PYGLCYP2C9ALDH1A1SLC1A3SLC1A2
SCHEMBL12557071 0.86 HTT (0.38) PYGLCYP2C9ALDH1A1SMN1; SMN2
SCHEMBL17327099 0.83 — —
SCHEMBL5146050 0.83 CTSK (0.49) CTSSCTSK
SCHEMBL10660662 0.83 SMN1; SMN2 (0.38) PYGLCYP2C9ALDH1A1SMN1; SMN2TYR
SCHEMBL10398797 0.83 SMN1; SMN2 (0.38) PYGLCYP2C9ALDH1A1SMN1; SMN2TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP claimed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US claimed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
CN-108349945-B HCV inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2021-10-29 — — CN disclosed
US-20210171506-A1 Process for Manufacturing Pibrentasvir Active Drug Substance ABBVIE INC. (US) 2021-06-10 — — US disclosed
CN-112638368-A Process for the manufacture of piretavir active pharmaceutical substance 艾伯维公司 2021-04-09 — — CN disclosed
CN-110382487-B Silicon-containing compounds for use against hepatitis c virus infection 正大天晴药业集团股份有限公司 2021-04-02 — — CN disclosed
US-20210053981-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
US-20210053981-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
EP-3778606-A2 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2021-02-17 — — EP disclosed
US-10807990-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-20 — — US disclosed
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-10-21 — — US disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 — — WO disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 — — WO disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 — — US disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 — — US disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 — — US disclosed
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-16 — — US disclosed
WO-2010099527-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2010-09-02 — — WO disclosed
WO-2010091413-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267634-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PYGL 88/4885CYP2C9 3780/4885ALDH1A1 2858/4885
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 PYGL 234/4885CYP2C9 324/4885ALDH1A1 201/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PYGL 88/4885CYP2C9 3780/4885ALDH1A1 2858/4885
US-10807990-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 PYGL 844/4885CYP2C9 3743/4885ALDH1A1 3925/4885
US-20100266543-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 PYGL 226/4885CYP2C9 262/4885ALDH1A1 250/4885
US-20210171506-A1 Process for Manufacturing Pibrentasvir Active Drug Substance CYP3A5, CYP3A4, HAVCR2 PYGL 120/4885CYP2C9 21/4885ALDH1A1 1112/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PYGL 88/4885CYP2C9 3780/4885ALDH1A1 2858/4885
US-20210053981-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 PYGL 844/4885CYP2C9 3743/4885ALDH1A1 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.